Targeting IL-8 and Its Receptors in Prostate Cancer: Inflammation, Stress Response, and Treatment Resistance
Cancers · 08.08.2024 · 16 (16) · 2797
DOI: 10.3390/cancers16162797 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 08.08.2024. Verfasst von Shauna McClelland und 5 weiteren Autor:innen. Beteiligte Einrichtung: Patrick G Johnston Centre for Cancer Research, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, 97 Lisburn Road, Be…. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 166 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Institutional: QUB Academic Lab Start-up Fund; Grant: BBSRC CAST Studentship, QUB Academic Lab Start-up Fund; Grant: BBSRC CAST Studentship.
Abstract (Originalsprache)
This review delves into the intricate roles of interleukin-8 (IL-8) and its receptors, CXCR1 and CXCR2, in prostate cancer (PCa), particularly in castration-resistant (CRPC) and metastatic CRPC (mCRPC). This review emphasizes the crucial role of the tumour microenvironment (TME) and inflammatory cytokines in promoting tumour progression and response to tumour cell targeting agents. IL-8, acting through C-X-C chemokine receptor type 1 (CXCR1) and type 2 (CXCR2), modulates multiple signalling pathways, enhancing the angiogenesis, proliferation, and migration of cancer cells. This review highlights the shift in PCa research focus from solely tumour cells to the non-cancer-cell components, including vascular endothelial cells, the extracellular matrix, immune cells, and the dynamic interactions within the TME. The immunosuppressive nature of the PCa TME significantly influences tumour progression and resistance to emerging therapies. Current treatment modalities, including androgen deprivation therapy and chemotherapeutics, encounter persistent resistance and are complicated by prostate cancer’s notably “immune-cold” nature, which limits immune system response to the tumour. These challenges underscore the critical need for novel approaches that both overcome resistance and enhance immune engagement within the TME. The therapeutic potential of inhibiting IL-8 signalling is explored, with studies showing enhanced sensitivity of PCa cells to treatments, including radiation and androgen receptor inhibitors. Clinical trials, such as the ACE trial, demonstrate the efficacy of combining CXCR2 inhibitors with existing treatments, offering significant benefits, especially for patients with resistant PCa. This review also addresses the challenges in targeting cytokines and chemokines, noting the complexity of the TME and the need for precision in therapeutic targeting to avoid side effects and optimize outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Patrick G Johnston Centre for Cancer Research, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7AE, UK.
- Bioscience Early Oncology, AstraZeneca, Cambridge CB2 0AA, UK.
ORCID-Profile: Cristina Branco, Cath Eberlein, Melissa J LaBonte
Förderung
- Institutional: QUB Academic Lab Start-up Fund; Grant: BBSRC CAST Studentship
- QUB Academic Lab Start-up Fund; Grant: BBSRC CAST Studentship
Zitieren
APA
McClelland, S., Maxwell, P. J., Branco, C., Barry, S. T., Eberlein, C., & LaBonte, M. J. (2024). Targeting IL-8 and Its Receptors in Prostate Cancer: Inflammation, Stress Response, and Treatment Resistance. Cancers, 16(16), 2797. https://doi.org/10.3390/cancers16162797
Vancouver
McClelland S, Maxwell PJ, Branco C, Barry ST, Eberlein C, LaBonte MJ. Targeting IL-8 and Its Receptors in Prostate Cancer: Inflammation, Stress Response, and Treatment Resistance. Cancers. 2024;16(16):2797. doi:10.3390/cancers16162797
BibTeX
@article{McClelland2024,
author = {McClelland, Shauna and Maxwell, Pamela J and Branco, Cristina and Barry, Simon T and Eberlein, Cath and LaBonte, Melissa J},
title = {Targeting IL-8 and Its Receptors in Prostate Cancer: Inflammation, Stress Response, and Treatment Resistance},
journal = {Cancers},
year = {2024},
volume = {16},
number = {16},
pages = {2797},
doi = {10.3390/cancers16162797}
}
EUVIMED